- Clinical guidelines
- Clinical Guidelines Network
- Optimal cancer care pathways
- Genetics Directory
- CALD Directory
- Patient fact sheets
- Primary care resources
- Cancer Forum
- Online learning
- Oncology education
- Events and conferences
- kNOw cancer risks at work
Clinical Practice Guidelines PSA Testing and Early Management of Test-Detected Prostate Cancer
The Clinical Practice Guidelines: PSA Testing and Early Management of Test-Detected Prostate Cancer were developed through a partnership of the Prostate Cancer Foundation of Australia (PCFA) and Cancer Council Australia.
For the first time, these guidelines provide health professionals access to evidence-based recommendations for using the prostate specific antigen (PSA) blood test to assess prostate cancer risk and manage test-detected patients. The recommendations also cover matters such as retesting, active surveillance, watchful waiting and biopsy.
The recommendations in these guidelines are approved by the CEO of the National Health and Medical Research Council (NHMRC). In granting approval, NHMRC is satisfied that the guideline recommendations are systematically derived, based on the identification and synthesis of the best available scientific evidence, and developed for health professionals practicing in an Australian health care setting.
The guidelines were launched in January 2016.
Clincial Practice Guidelines
- Evidence-based recommendations for the management of Localised Prostate Cancer
- Clinical Practice Guidelines for the Management of Locally Advanced and Metastatic Prostate Cancer 2010
- Localised Prostate Cancer: a guide for men and their families 2010
- Advanced Prostate Cancer: a guide for men and their families 2009
To obtain a free copy, of Localised Prostate Cancer: a guide for men and their families 2010 and Advanced Prostate Cancer: a guide for men and their families 2009, please call Cancer Council 13 11 20.
This page was last updated on: Wednesday, January 20, 2016